Ocular allergy in pediatric practice

Current Allergy and Asthma Reports

Volumn 6, Issue 4, 2006, Pages 306-311

  Abelson, Mark B ^a   Granet, David ^b  

^a ORA Clinical Research and Development   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTAZOLINE; ANTIHISTAMINIC AGENT; AZELASTINE; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE RECEPTOR ANTAGONIST; DECONGESTIVE AGENT; EMEDASTINE; EPINASTINE; KETOTIFEN; LEVOCABASTINE; LODOXAMIDE; NEDOCROMIL; NONSTEROID ANTIINFLAMMATORY AGENT; OLOPATADINE; PEMIROLAST; PHENIRAMINE; TACROLIMUS;

ABDOMINAL DISCOMFORT; ALLERGIC CONJUNCTIVITIS; ALLERGY; ATOPIC KERATOCONJUNCTIVITIS; BLEEDING; CATARACT; CHILD; CHILDHOOD DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONJUNCTIVA DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG MECHANISM; EARLY DIAGNOSIS; ENVIRONMENTAL SANITATION; EYE DISEASE; FREQUENCY ANALYSIS; GLAUCOMA; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOTHERAPY; MEDICAL SPECIALIST; PEDIATRICS; PERSONAL HYGIENE; REVIEW; TACHYPHYLAXIS; TASTE DISORDER; VERNAL CONJUNCTIVITIS;

ANTI-ALLERGIC AGENTS; CHILD; CONJUNCTIVITIS, ALLERGIC; HUMANS; HYPERSENSITIVITY; KERATOCONJUNCTIVITIS; PEDIATRICS;

EID: 33745941775     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-006-0064-x     Document Type: Review

References (45)

1. Nathan R, Meltzer E, Selner J, Storms W: Prevalence of allergic rhinitis in the United States. J Allergy Clin Immunol 1997, 99:S808-S814.
2. Meltzer EO: Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol 2001, 108:S45-S53.
3. Juniper EF, Guyatt GH, Dolovich J: Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 1994, 93:413-423.
4. De Freitas D, Sato EH, Rizzo L: T Lymphocytes. In Allergic Diseases of the Eye. Edited by Abelson MB. Philadelphia: WB Saunders; 2001:37.
5. Irani AM, Schwartz LB: Mast cell heterogeneity. Clin Exp Allergy 1989, 19:143-155.
6. Dart JK, Buckley RJ, Monnickendan M, Prasad J: Perennial allergic conjunctivitis: definition, clinical characteristics, and prevalence. A comparison with seasonal allergic conjunctivitis. Trans Ophthalmol Soc UK 1986, 105:513-520.
7. Udell IJ, Gleich GJ, Allansmith MR, et al.: Eosinophil granule major basic protein and Charcot-Leyden crystal protein in human tears. Am J Ophthalmol 1981, 92:824-828.
8. Abelson MB, Leonardi AA, Smith LM, et al.: Histaminase activity in patients with vernal keratoconjunctivitis. Ophthalmology 1995, 102:1958-1963.
9. Abelson MB, Butrus SI, Weston JH, Rosner B: Tolerance and absence of rebound vasodilation following topical ocular decongestant usage. Ophthalmology 1984, 91:1364-1367.
10. Lanier BQ, Abelson MB, Berger WE, et al.: Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge. Clin Ther 2002, 24:1161-1174.
11. Ousler GW, Wilcox KA, Gupta G, Abelson MB: An evaluation of the ocular drying effects of two systemic antihistamines: loratadine and cetirizine hydrochloride. Ann Allergy Asthma Immunol 2004, 93:460-464.
12. Kjellman NI, Andersson B: Terfenadine reduces skin and conjunctival reactivity in grass pollen allergic children. Clin Allergy 1986, 16:441-449.
13. Ciprandi G, Buscaglia S, Marchesi E, et al.: Protective effect of loratadine on late phase reaction induced by conjunctival provocation test. Int Arch Allergy Immunol 1993, 100:185-189.
14. Santos CI, Huang AJ, Abelson MB, et al.: Efficacy of lodoxamide 0.1% ophthalmic solution in resolving corneal epitheliopathy associated with vernal keratoconjunctivitis. Am J Ophthalmol 1994, 117:488-497.
15. Abelson MB, Berdy GJ, Mundorf T, et al.: Pemirolast study group. Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies. J Ocul Pharmacol Ther 2002, 18:475-488.
16. Verin PH, Dicker ID, Mortemousque B: Nedocromil sodium eye drops are more effective than sodium cromoglycate eye drops for the long-term management of vernal keratoconjunctivitis. Clin Exp Allergy 1999, 29:529-536.
17. Sharif NA, Xu SX, Miller ST, et al.: Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J Pharmacol Exp Ther 1996, 278:1252-1261.
18. Yanni JM, Stephens DJ, Miller ST, et al.: The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther 1996, 12:389-400.
19. Yanni JM, Miller ST, Gamache DA, et al.: Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann. Allergy Asthma Immunol 79, 541-545, 1997.
20. Yanni JM, Sharif NA, Gamache DA, et al.: A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: effects of new topical ocular drugs. Acta Ophthalmol Scand Suppl 1999, 228:33-37.
21. Cook EB, Stahl JL, Barney NP, Graziano FM: Olopatadine inhibits NFalpha release from human conjunctival mast cells. Ann Allergy Asthma Immunol 2000, 84:504-508.
22. Leonardi A, Abelson MB:. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clin Ther 2003, 25:2539-2552.
23. Katelaris CH, Cipriandi G, Missotten L, et al.: A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. Clin Ther 2002, 24:1561-1575.
24. Butrus S, Greiner JV, Discepola M, Finegold I: Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. Clin Ther 2000, 22:1462-1472.
25. Ciprandi G, Turner D, Gross R: Double-masked, randomized, parallel-group study comparing olopatadine 0.1% ophthalmic solution with cromolyn sodium 2% and levocabastine 0.05% ophthalmic preparations in children with seasonal allergic conjunctivitis. Curr Ther Res Clin Exp 2004, 65:186-199.
26. Berdy GJ, Stoppel JO, Epstein AB: Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model. Clin Ther 2002, 24:918-929.
27. Deschenes J, Discepola M, Abelson MB: Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model. Acta Ophthalmol Scand Suppl 1999, 228:47-52.
28. Berdy GJ, Spangler DL, Bensch G, et al.: A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model. Clin Ther 2000, 22:826-833.
29. Spangler DL, Bensch G, Berdy GJ: Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clin Ther 2001, 23:1272-1280.
30. Lanier R, Finegold I, D'Arienzo P, et al.: Clinical efficacy of olopatadine vs. epinastine ophthalmic solution in the conjunctival allergen challenge model. Curr Med Res Opin 2004, 20:P1-P7.
31. Artal MN, Luna JD, Discepola M: A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%. Acta Ophthalmol Scand Suppl 2000, 230:64-65.
32. Leonardi A, Zafirakis P: Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preference. Curr Med Res Opin 2004, 20:1167-1173.
33. Berger W, Abelson MB, Gomes PJ, et al.: Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy. Ann Allergy Asthma Immunol 2005, 95:361-371.
34. Novartis: Zaditor Prescribing Information. http://www.pharma.us.novartis.com/product/pi/pdf/zaditor.pdf. Accessed January 18, 2005.
35. Abelson MB: A review of olopatadine for the treatment of ocular allergy. Expert Opin Pharmacother 2004, 5:1979-1994.
36. Aguilar A: Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. Acta Ophthalmol Scand Suppl 2000, 230:52-55.
37. Sabbah A, Marzetto M: Azelastine eye drops in the treatment of seasonal allergic conjunctivitis or rhinoconjunctivitis in young children. Curr Med Res Opin 1998, 14:161-170.
38. Allergan: Elestat Prescribing Information. http://www.elestat.com/ practitioners/faqs.html#gi1. Accessed January 29, 2006.
39. Amon U, Gibbs BF, Buss G, Nitschke M: In vitro investigations with the histamine H1 receptor antagonist, epinastine (WAL 801 CL), on isolated human allergic effector cells. Inflamm Res 2000, 49:112-116.
40. Eakins KE: Prostaglandin and inflammatory reactions in the eye. Methods Find Exp Clin Pharmacol 1980, 2:17.
41. Abelson MB, Butrus SI, Weston JH: Aspirin therapy in vernal conjunctivitis. Am J Ophthalmol 1983, 95:502-505.
42. Akpek EK, Dart JK, Watson S, et al.: A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology 2004, 111:476-482.
43. Cetinkaya A, Akova YA, Dursun D, Pelit A: Topical cyclosporine in the management of shield ulcers. Cornea 2004, 23:194-200.
44. Sperr WR, Agis H, Semper H, et al.: Inhibition of allergen-induced histamine release from human basophils by cyclosporine A and FK-506. Int Arch Allergy Immunol 1997, 114:68-73.
45. Spiegelberg HL, Orozco EM, Roman M, Raz E: DNA immunization: a novel approach to allergen-specific immunotherapy. Allergy 1997, 52:964-970.